Article
Visual acuity benefit seen with SnET2 photodynamic therapy
Fort Lauderdale, FL-The investigational drug tin ethyl etiopurpurin (SnET2) produced a visual acuity benefit and slowed the development of neovascular lesions in two phase III trials of SnET2 photodynamic therapy (PDT) (Miravant Medical Technologies) for the treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration, said Edgar L. Thomas, MD, Retina-Vitreous Associates, Los Angeles.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
